This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through July 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
Why CELC Stock Declined 15% in a Week Despite a Major FDA Win
by Zacks Equity Research
Celcuity slides 15% despite FDA approval of Revtorpyk as investors focus on a late Q3 2026 launch that delays commercial sales and near-term revenues.
CELCNegative Net Change AZNPositive Net Change NVSNegative Net Change PFENegative Net Change
biotechs medical pharmaceuticals
Novartis Q2 Earnings & Revenues Top Estimates, Key Drugs Perform Well
by Zacks Equity Research
Novartis tops Q2 earnings and revenue estimates as growth from key brands offsets generic pressure, while reaffirming 2026 guidance and advancing acquisitions.
NVSNegative Net Change RHHBYPositive Net Change NVAXNegative Net Change LQDANegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
DYN Stock Rises 19.2% in 3 Months: What's Driving the Rally?
by Zacks Equity Research
Dyne gains momentum as FDA priority review for its lead DMD therapy and progress in its DM1 program strengthen confidence in its pipeline.
DYNPositive Net Change NBIXPositive Net Change AMRNNegative Net Change LQDANegative Net Change
biotechs
Acadia Gets FDA's Fast Track Tag for Alzheimer's Disease Candidate
by Zacks Equity Research
ACAD wins FDA's Fast Track status for remlifanserin in Alzheimer's disease psychosis as its phase II data readout approaches and phase III enrollment advances.
ACADPositive Net Change NBIXPositive Net Change AMRNNegative Net Change LQDANegative Net Change
biotechnology biotechs medical pharmaceuticals
Entera Bio Stock Rallies 35% in a Month: Here's What You Should Know
by Zacks Equity Research
ENTX stock jumps 35% in a month after the FDA backs a streamlined phase III plan for oral osteoporosis candidate EB613, bringing a key regulatory milestone into focus.
ENTXNegative Net Change LLYPositive Net Change NBIXPositive Net Change LQDANegative Net Change
biotechnology biotechs medical pharmaceuticals
HALO Inks Deal With INCY to Support Cancer Therapy Development
by Zacks Equity Research
Halozyme grants ENHANZE rights to Incyte for developing subcutaneous cancer therapy formulations, aiming to improve treatment convenience for patients.
INCYPositive Net Change HALOPositive Net Change RHHBYPositive Net Change JNJPositive Net Change
biotechs
3 Promising Genomics Stocks to Add to Your Portfolio in 2026
by Ekta Bagri
Genomics is reshaping healthcare, and these three stocks - MYGN, SANA and WVE - stand out as rapid advances in personalized medicine and synthetic biology continue to transform the industry.
MYGNNegative Net Change WVEPositive Net Change SANANegative Net Change ILMNNegative Net Change NTLANegative Net Change CRSPNegative Net Change
biotechnology biotechs cell-therapy gene-editing gene-therapy genomics pharmaceuticals
ZNTL Stock Rises 28% in 3 Months: What's Driving the Rally?
by Zacks Equity Research
Zentalis shares climb 28% over the past three months as optimism builds around azenosertib's ovarian cancer program.
ZNTLNegative Net Change NBIXPositive Net Change AMRNNegative Net Change LQDANegative Net Change
biotechs
Does EU Approval of Wegovy Pill Change NVO's Competitive Story?
by Ahan Chakraborty
Novo Nordisk wins EU approval for the first GLP-1 obesity tablet, expanding Wegovy's reach, but tougher competition keeps the broader investment outlook in focus.
NVOPositive Net Change LLYPositive Net Change VKTXNegative Net Change GPCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
uniQure Trends to Watch as Gene Therapy Bets Shift Beyond Hemgenix
by Ekta Bagri
QURE is sharpening its gene therapy focus through faster regulatory pathways, a streamlined business model and CNS pipeline expansion, with AMT-130 at the center.
QURENegative Net Change SRPTNegative Net Change PTCTNegative Net Change
biotechnology biotechs pharmaceuticals